Cognition Therapeutics, Inc.

NASDAQ (USD): Cognition Therapeutics, Inc. (CGTX)

Last Price

0.813

Today's Change

+0.358 (78.68%)

Day's Change

0.752 - 1.29

Trading Volume

241,671,991

Overview

Market Cap

33 Million

Shares Outstanding

41 Million

Avg Volume

1,563,382

Avg Price (50 Days)

0.47

Avg Price (200 Days)

1.26

PE Ratio

-0.85

EPS

-0.96

Earnings Announcement

25-Mar-2025

Previous Close

0.45

Open

1.15

Day's Range

0.752 - 1.29

Year Range

0.34 - 2.95

Trading Volume

241,828,081

Price Change Highlight

1 Day Change

78.87%

5 Day Change

62.74%

1 Month Change

75.86%

3 Month Change

35.82%

6 Month Change

-59.52%

Ytd Change

-58.06%

1 Year Change

-52.14%

3 Year Change

-84.05%

5 Year Change

-93.63%

10 Year Change

-93.63%

Max Change

-93.63%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment